- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Most Popular Stocks
U.S. Pharmaceuticals & Biotech Most Popular Stocks
Results
1140
Most Popular Stocks on the market
1140 companies
Aurinia Pharmaceuticals
Market Cap: US$1.7b
A biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs.
AUPH
US$12.85
7D
-0.3%
1Y
79.5%
GRAIL
Market Cap: US$1.7b
A commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.
GRAL
US$48.26
7D
21.9%
1Y
254.9%
Vera Therapeutics
Market Cap: US$1.7b
A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases.
VERA
US$26.96
7D
2.4%
1Y
-41.0%
MannKind
Market Cap: US$1.6b
A biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States.
MNKD
US$5.33
7D
-5.0%
1Y
-15.0%
BioCryst Pharmaceuticals
Market Cap: US$1.6b
A biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases.
BCRX
US$7.65
7D
-3.9%
1Y
0.9%
Twist Bioscience
Market Cap: US$1.6b
Manufactures and sells synthetic DNA-based products.
TWST
US$26.75
7D
-4.3%
1Y
-43.2%
Viridian Therapeutics
Market Cap: US$1.6b
Engages in discovering, developing, and commercializing treatments for serious and rare diseases.
VRDN
US$19.08
7D
-2.8%
1Y
-17.3%
Anbio Biotechnology
Market Cap: US$1.6b
Provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally.
NNNN
US$35.82
7D
-15.5%
1Y
n/a
Phibro Animal Health
Market Cap: US$1.6b
Operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific.
PAHC
US$38.04
7D
-6.2%
1Y
72.1%
Harmony Biosciences Holdings
Market Cap: US$1.5b
A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
HRMY
US$27.04
7D
-17.1%
1Y
-32.0%
Vericel
Market Cap: US$1.5b
A commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.
VCEL
US$29.84
7D
-6.3%
1Y
-32.3%
Avadel Pharmaceuticals
Market Cap: US$1.5b
Operates as a biopharmaceutical company in the United States.
AVDL
US$15.33
7D
-5.5%
1Y
21.7%
10x Genomics
Market Cap: US$1.5b
A life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific.
TXG
US$11.95
7D
-9.9%
1Y
-46.4%
Ardelyx
Market Cap: US$1.5b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$5.96
7D
-7.2%
1Y
-6.3%
Amylyx Pharmaceuticals
Market Cap: US$1.5b
A clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.
AMLX
US$13.82
7D
4.3%
1Y
331.9%
Structure Therapeutics
Market Cap: US$1.5b
A clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States.
GPCR
US$24.99
7D
7.6%
1Y
-39.8%
Biohaven
Market Cap: US$1.5b
Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide.
BHVN
US$13.82
7D
-11.0%
1Y
-73.0%
Dianthus Therapeutics
Market Cap: US$1.4b
A clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases.
DNTH
US$35.84
7D
-7.8%
1Y
32.6%
AbCellera Biologics
Market Cap: US$1.4b
Engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
ABCL
US$4.65
7D
-1.5%
1Y
81.6%
Tilray Brands
Market Cap: US$1.4b
A lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally.
TLRY
US$1.19
7D
-5.6%
1Y
-31.6%
Novavax
Market Cap: US$1.4b
A biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally.
NVAX
US$8.34
7D
-2.2%
1Y
-31.3%
Janux Therapeutics
Market Cap: US$1.4b
A clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer.
JANX
US$21.77
7D
-10.8%
1Y
-53.3%
Azenta
Market Cap: US$1.4b
Provides biological and chemical compound sample exploration and management solutions for the life sciences market in the United States, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally.
AZTA
US$28.75
7D
-7.4%
1Y
-41.5%
Sierra Oncology
Market Cap: US$1.3b
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs.
SRRA
US$54.99
7D
0.06%
1Y
179.4%
Arcus Biosciences
Market Cap: US$1.3b
A clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
RCUS
US$12.37
7D
-0.6%
1Y
-19.6%
Syndax Pharmaceuticals
Market Cap: US$1.3b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$15.03
7D
-2.7%
1Y
-17.2%
Xeris Biopharma Holdings
Market Cap: US$1.3b
A commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois.
XERS
US$7.85
7D
-5.4%
1Y
177.4%
Stoke Therapeutics
Market Cap: US$1.3b
An early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression.
STOK
US$22.95
7D
-2.3%
1Y
87.2%
Amphastar Pharmaceuticals
Market Cap: US$1.2b
A bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.
AMPH
US$26.36
7D
-3.9%
1Y
-44.9%
Rapport Therapeutics
Market Cap: US$1.2b
Operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders.
RAPP
US$24.97
7D
-8.7%
1Y
21.6%
Tourmaline Bio
Market Cap: US$1.2b
Operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases.
TRML
US$47.72
7D
0.06%
1Y
92.0%
Zymeworks
Market Cap: US$1.2b
A clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID).
ZYME
US$16.16
7D
-2.0%
1Y
29.6%
CureVac
Market Cap: US$1.2b
A biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
CVAC
US$5.35
7D
0%
1Y
77.2%
YD Bio
Market Cap: US$1.2b
A biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs.
YDES
US$14.25
7D
-26.2%
1Y
26.5%
Sionna Therapeutics
Market Cap: US$1.2b
A clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF).
SION
US$27.50
7D
18.4%
1Y
n/a
Innoviva
Market Cap: US$1.2b
Engages in the development and commercialization of pharmaceutical products in the United States and internationally.
INVA
US$18.57
7D
-6.6%
1Y
-2.0%